Share This Article:

Natural and Semi-Synthetic Pseudoguaianolides as Inhibitors of NF-κB

Abstract Full-Text HTML Download Download as PDF (Size:2906KB) PP. 833-847
DOI: 10.4236/jbise.2014.710083    2,990 Downloads   3,494 Views   Citations


Damsin (1) is a natural pseudoguaianolide sesquiterpene that inhibits NF-κB, a protein complex that controls the transcription of DNA in mammalian cells, and has a potential for standing model for the development of new anti-cancer lead structures. In order to do a preliminary structure-activity study and improve the anti-cancer activity, fourteen derivatives and analogs were prepared and evaluated. These were chosen to represent both structural diversity and structural novelty. The importance of α methylene-γ-lactone moiety for the anti-cancer activity was confirmed, even though other features in the scaffold were shown to be important for the activity. In some cases a new substitution negatively affected the initial activity, however, two analogues, indolo [3,2-c]-4-desoxydamsin (5) and ambrosin (6), were found to be more potent.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Villagomez, R. , Collado, J. , Muñoz, E. , Almanza, G. and Sterner, O. (2014) Natural and Semi-Synthetic Pseudoguaianolides as Inhibitors of NF-κB. Journal of Biomedical Science and Engineering, 7, 833-847. doi: 10.4236/jbise.2014.710083.


[1] Li, Q. and Verma, I.M. (2002) NF-κB Regulation in the Immune System. Nature Reviews Immunology, 2, 725-734.
[2] Gilmore, T.D. (2006) Introduction to NF-κB: Players, Pathways, Perspectives. Oncogene, 25, 6680-6684.
[3] Hayden, M.S. and Ghosh, S. (2008) Shared Principles in NF-κB Signaling. Cell, 132, 344-362.
[4] Ben-Neriah, Y. and Karin, M. (2011) Inflammation Meets Cancer, with NF-κB as the Matchmaker. Nature Immunology, 12, 715-723.
[5] Karin, M. (2006) NF-κB and Cancer: Mechanisms and Targets. Molecular Carcinogenesis, 45, 355-361.
[6] Nakanishi, C. and Toi, M. (2005) Nuclear Factor-κB Inhibitors as Sensitizers to Anticancer Drugs. Nature Reviews Cancer, 5, 297-309.
[7] Kim, H.J., Hawke, N. and Baldwin, A.S. (2006) NF-κB and IKK as Therapeutic Targets in Cancer. Cell Death and Differentiation, 13, 738-747.
[8] Orlowski, R.Z. and Baldwin Jr., A.S. (2002) NF-κB as a Therapeutic Target in Cancer. Trends in Molecular Medicine, 8, 385-389.
[9] Yamamoto, Y. and Gaynor, R.B. (2001) Therapeutic Potential of Inhibition of the NF-κB Pathway in the Treatment of Inflammation and Cancer. The Journal of Clinical Investigation, 107, 135-142.
[10] Brown, R.E., Tan, D., Taylor, J.S., Miller, M., Prichard, J.W. and Kott, M.M. (2007) Morphoproteomic Confirmation of Constitutively Activated mTOR, ERK, and NF-κB Pathways in High Risk Neuro-Blastoma, with Cell Cycle and Protein Analyte Correlates. Annals of Clinical & Laboratory Science, 37, 141-147.
[11] Bours, V., Bentires-Alj, M., Hellin, A.C., Viatour, P., Robe, P., Delhalle, S., Benoit, V. and Merville, M.P. (2000) Nuclear Factor-κB, Cancer, and Apoptosis. Biochemical Pharmacology, 60, 1085-1089.
[12] Baldwin, A.S. (2001) Control of Oncogenesis and Cancer Therapy Resistance by the Transcription Factor NF-κB. Journal of Clinical Investigation, 107, 241-246.
[13] Dolcet, X., Llobet, D., Pallares, J. and Matias-Guiu, X. (2005) NF-κB in Development and Progression of Human Cancer. Virchows Archiv, 446, 475-482.
[14] Karin, M., Cao, Y., Greten, F.R. and Li, Z.W. (2002) NF-κB in Cancer: From Innocent Bystander to Major Culprit. Nature Reviews Cancer, 2, 301-310.
[15] Pacifico, F. and Leonardi, A. (2006) NF-κB in Solid Tumors. Biochemical Pharmacology, 72, 1142-1152.
[16] Verma, I.M. (2004) Nuclear Factor (NF)-κB Proteins: Therapeutic Targets. Annals of the Rheumatic Diseases, 63, ii57-ii61.
[17] Picman, A.K. (1986) Biological Activities of Sesquiterpene Lactones. Biochemical Systematics and Ecology, 14, 255-281.
[18] Ghantous, A., Gali-Muhtasib, H., Vuorela, H., Saliba, N.A. and Darwiche, N. (2010) What Made Sesquiterpene Lactones Reach Cancer Clinical Trials? Drug Discovery Today, 15, 668-678.
[19] Zhang, S., Won, Y.K., Ong, C.N. and Shen, H.M. (2005) Anti-Cancer Potential of Sesquiterpene Lactones: Bioactivity and Molecular Mechanisms. Current Medicinal Chemistry-Anti-Cancer Agents, 5, 239-249.
[20] Salminen, A., Lehtonen, M., Suuronen, T., Kaarniranta, K. and Huuskonen, J. (2008) Terpenoids: Natural Inhibitors of NF-κB Signaling with Anti-Inflammatory and Anticancer Potential. Cellular and Molecular Life Sciences, 65, 2979-2999.
[21] Kreuger, M.R., Grootjans, S., Biavatti, M.W., Vandenabeele, P. and D’Herde, K. (2012) Sesquiterpene Lactones as Drugs with Multiple Targets in Cancer Treatment: Focus on Parthenolide. Anti-Cancer Drugs, 23, 883-896.
[22] Scotti, M.T., Fernandes, M.B., Ferreira, M.J.P. and Emerenciano, V.P. (2007) Quantitative Structure-Activity Relationship of Sesquiterpene Lactones with Cytotoxic Activity. Bioorganic & Medicinal Chemistry, 15, 2927-2934.
[23] Siedle, B., García-Piñeres, A.J., Murillo, R., Schulte-Mönting, J., Castro, V., Rüngeler, P., Klaas, C.A., Da Costa, F.B., Kisiel, W. and Merfort, I. (2004) Quantitative Structure-Activity Relationship of Sesquiterpene Lactones as Inhibitors of the Transcription Factor NF-κB. Journal of Medicinal Chemistry, 47, 6042-6054.
[24] Fernandes, M.B., Scotti, M.T., Ferreira, M.J.P. and Emerenciano, V.P. (2008) Use of Self-Organizing Maps and Molecular Descriptors to Predict the Cytotoxic Activity of Sesquiterpene Lactones. European Journal of Medicinal Chemistry, 43, 2197-2205.
[25] Schmidt, T.J. and Heilmann, J. (2002) Quantitative Structure-Cytotoxicity Relationships of Sesquiterpene Lactones Derived from Partial Charge (q)-Based Fractional Accessible Surface Area Descriptors (Q_frASAs). Quantitative Structure-Activity Relationships, 21, 277-287.<276::AID-QSAR276>3.0.CO;2-S
[26] Kupchan, S.M., Fessler, D.C., Eakin, M.A. and Giacobbe, T.J. (1970) Reactions of Alpha Methylene Lactone Tumor Inhibitors with Model Biological Nucelophiles. Science, 168, 376-378.
[27] Perkins, N.D. (2012) Cysteine 38 Holds the Key to NF-κB Activation. Molecular Cell, 45, 1-3.
[28] Rüngeler, P., Castro, V., Mora, G., Gören, N., Vichnewski, W., Pahl, H.L., Merfort, I. and Schmidt, T.J. (1999) Inhibition of Transcription Factor NF-κB by Sesquiterpene Lactones: A Proposed Molecular Mechanism of Action. Bioorganic & Medicinal Chemistry, 7, 2343-2352.
[29] Garcia-Pineres, A.J., Castro, V., Mora, G., Schmidt, T.J., Strunck, E., Pahl, H.L. and Merfort, I. (2001) Cysteine 38 in p65/NF-κB Plays a Crucial Role in DNA Binding Inhibition by Sesquiterpene Lactones. Journal of Biological Chemistry, 276, 39713-39720.
[30] Garcia-Pineres, A.J., Lindenmeyer, M.T. and Merfort, I. (2004) Role of Cysteine Residues of p65/NF-κB on the Inhibition by the Sesquiterpene Lactone Parthenolide and N-Ethyl Maleimide, and on Its Transactivating Potential. Life Sciences, 75, 841-856.
[31] Penarrieta, J.M., Soruco, M.L., Flores, Y. and Almanza, G.R. (2003) High Yield of Damsin, a Sesquiterpene with Antineoplasic Activity, in the Plant Species Franseria Artemisioides. Revista Boliviana de Química, 20, 32-36.
[32] Lee, K.H., Huang, E.S., Piantadosi, C., Pagano, J.S. and Geissman, T.A. (1971) Cytotoxicity of Sesquiterpene Lactones. Cancer Research, 31, 1649-1654.
[33] Doskotch, R.W. and Hufford, C.D. (1969) Damsin, the Cytotoxic Principle of Ambrosia Ambrosioides (Cav.) Payne. Journal of Pharmaceutical Sciences, 58, 186-188.
[34] De Leo, M., Saltos, M.B.V., Puente, B.F.N., De Tommasi, N. and Braca, A. (2010) Sesquiterpenes and Diterpenes from Ambrosia Arborescens. Phytochemistry, 71, 804-809.
[35] Villagomez, R., Rodrigo, G.C., Collado, I.G., Calzado, M.A., Muñoz, E., Åkesson, B., Sterner, O., Almanza, G.R. and Duan, R.D. (2013) Multiple Anticancer Effects of Damsin and Coronopilin Isolated from Ambrosia Arborescens on Cell Cultures. Anticancer Research, 33, 3799-3805.
[36] Herz, W., Anderson, G., Gibaja, S. and Raulais, D. (1969) Sesquiterpene Lactones of Some Ambrosia Species. Phytochemistry, 8, 877-881.
[37] Romo, J., Joseph-Nathan, P. and Díaz, F.A. (1964) The Constituents of Helenium aromaticum (Hook) Bailey: The Structures of Aromatin and Aromaticin. Tetrahedron, 20, 79-85.
[38] Shah, B.A., Taneja, S.C., Sethi, V.K., Gupta, P., Andotra, S.S., Chimni, S.S. and Qazi, G.N. (2007) The Formation of Novel 1,3-Dioxolanes: Atypical Baylis-Hillman Reaction of a Sesquiterpene Lactone Parthenin. Tetrahedron Letters, 48, 955-960.
[39] Shah, B.A., Kaur, R., Gupta, P., Kumar, A., Sethi, V.K., Andotra, S.S., Singh, J., Saxena, A.K. and Taneja, S.C. (2009) Structure-Activity Relationship (SAR) of Parthenin Ana-logues with Proapoptotic Activity: Development of Novel Anti-Cancer Leads. Bioorganic & Medicinal Chemistry Letters, 19, 4394-4398.
[40] Hejchman, E., Haugwitz, R.D. and Cushman, M. (1995) Synthesis and Cytotoxicity of Water-Soluble Ambrosin Prodrug Candidates. Journal of Medicinal Chemistry, 38, 3407-3410.
[41] Hooper, M., Kirby, G.C., Kulkarni, M.M., Kulkarni, S.N., Nagasampagi, B.A., O’Neill, M.J., Phillipson, J.D., Rojatkar, S.R. and Warhurst, D.C. (1990) Antimalarial Activity of Parthenin and Its Derivatives. European Journal of Medicinal Chemistry, 25, 717-723.
[42] Villagomez, R., Quiroz, M., Tito, A., Sterner, O. and Almanza, G.R. (2014) Natural Pseudoguaianolides Prepared from Damsin. Chem Nat Comp, submitted.
[43] Gemal, A.L. and Luche, J.L. (1981) Lanthanoids in Organic Synthesis. 6. Reduction of α.-enones by Sodium Borohydride in the Presence of Lanthanoid Chlorides: Synthetic and Mechanistic Aspects. Journal of the American Chemical Society, 103, 5454-5459.
[44] Wissner, A., Overbeek, E., Reich, M.F., Floyd, M.B., Johnson, B.D., Mamuya, N., Rosfjord, E.C., Discafani, C., Davis, R., Shi, X., Rabindran, S.K., Gruber, B.C., Ye, F., Hallett, W.A., Nilakantan, R., Shen, R., Wang, Y.-F., Greenberger, L.M. and Tsou, H.R. (2002) Synthesis and Structure-Activity Relationships of 6,7-Disubstituted 4-Anilinoquinoline-3-Carbonitriles. The Design of an Orally Active, Irreversible Inhibitor of the Tyrosine Kinase Activity of the Epidermal Growth Factor Receptor (EGFR) and the Human Epidermal Growth Factor Receptor-2 (HER-2). Journal of Medicinal Chemistry, 46, 49-63.
[45] Bagal, S.K., Adlington, R.M., Brown, R.A.B. and Baldwin, J.E. (2005) Regioselectivity of Dimerisation of Butenolides via Captodative Stabilised Radicaloid Intermediates. Tetrahedron Letters, 46, 4633-4637.
[46] Han, C., Barrios, F.J., Riofski, M.V. and Colby, D.A. (2009) Semisynthetic Derivatives of Sesquiterpene Lactones by Palladium-Catalyzed Arylation of the α-Methylene-γ-lactone Substructure. Journal of Organic Chemistry, 74, 7176-7179.
[47] Belovodskii, A.V., Shul’ts, E.E., Shakirov, M.M. and Tolstikov, G.A. (2009) Sesquiterpene Metylenelactones in a Palladium-Catalyzed Cross-Coupling Reaction. Doklady Chemistry, 426, 138-142.
[48] Rosamilia, A.E., Giarrusso, M.A., Scott, J.L. and Strauss, C.R. (2006) A Direct, Efficient Synthesis of Unsymmetrically Substituted bis(arylidene)alkanones. Green Chemistry, 8, 1042-1050.
[49] Chen, M.S. and White, M.C. (2007) A Predictably Selective Aliphatic C-H Oxidation Reaction for Complex Molecule Synthesis. Science, 318, 783-787.
[50] Lee, K.H., Furukawa, H. and Huang, E.S. (1972) Antitumor Agents. 3. Synthesis and Cytotoxic Activity of Helenalin Amine Adducts and Related Derivatives. Journal of Medicinal Chemistry, 15, 609-611.
[51] Muñoz, E., Blazquez, M.V., Ortiz, C., Gomez-Diaz, C. and Navas, P. (1997) Role of Ascorbate in the Activation of NF-κB by Tumour Necrosis Factor-Alpha in T-Cells. Biochemical Journal, 325, 23-28.
[52] Castro, V., Rüngeler, P., Murillo, R., Hernandez, E., Mora, G., Pahl, H.L. and Merfort, I. (2000) Study of Sesquiterpene Lactones from Milleria quinqueflora on Their Anti-Inflammatory Activity Using the Transcription Factor NF-κB as Molecular Target. Phytochemistry, 53, 257-263.
[53] Kupchan, S.M., Giacobbe, T.J., Krull, I.S., Thomas, S.M., Eakin, M.A. and Fessler, D.C. (1970) Tumor Inhibitors. LVII. Reaction of Endocyclic .Alpha.,.Beta.-Unsaturated .Gamma.-Lactones with Thiols. Journal of Organic Chemistry, 35, 3539-3543.

comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.